Wayne Paterson has been appointed as non-executive chairman of the Admedus Board of Directors, with immediate effect. This follows the resignation of Chris Catlow who held the position for five years.
Graeme Rowley, who served as a non-executive director for five years, has also resigned. Catlow and Rowley have been involved with the group for the past 11 years holding non-executive director positions for subsidiary companies.
“The Board and I would like to thank Chris and Graeme for their work in establishing Admedus and their help in growing it into the diversified healthcare company it is today. Their contributions have been invaluable over the years”, says Paterson. “The board now looks forward to applying our collective energies to the next chapter of Admedus’ development and further improving patient outcomes and as a result shareholder value”.
Chief executive officer Lee Rodne comments that, “the Admedus board now consists of directors with extensive experience in each of our core product areas with specific backgrounds in sales, marketing, general management and corporate governance. We look forward to their ongoing input to our outstanding management team.”
Paterson joined the Admedus board in 2015 having spent 25 years in the global pharmaceutical industry, managing diverse and complex global operations at Roche and Merck. Over his career he has been responsible for substantial revenues and operations and held the positions of president Europe, Canada and Australia, president of Emerging markets, president of Japan, global head of Cardiovascular and general medicine amongst others. Paterson is also a non-executive director of a US National Association of Securities Dealers Automated Quotation (NASDAQ) listed molecular diagnostics company.
